Literature DB >> 35505016

In Vivo Models for Studying Interstitial Photodynamic Therapy of Locally Advanced Cancer.

Gal Shafirstein1, Emily Oakley2, Sasheen Hamilton2, Michael Habitzruther2, Sarah Chamberlain2, Sandra Sexton3, Leslie Curtin3, David A Bellnier2.   

Abstract

Interstitial photodynamic therapy (I-PDT) is a promising therapy considered for patients with locally advanced cancer. In I-PDT, laser fibers are inserted into the tumor for effective illumination and activation of the photosensitizer in a large tumor. The intratumoral light irradiance and fluence are critical parameters that affect the response to I-PDT. In vivo animal models are required to conduct light dose studies, to define optimal irradiance and fluence for I-PDT. Here we describe two animal models with locally advanced tumors that can be used to evaluate the response to I-PDT. One model is the C3H mouse bearing large subcutaneous SCCVII carcinoma (400-600 mm3). Using this murine model, multiple light regimens with one or two optical fibers with cylindrical diffuser ends (cylindrical diffuser fiber, CDF) can be used to study tumor response to I-PDT. However, tissue heating may occur when 630 nm therapeutic light is delivered through CDF at an intensity ≥60 mW/cm and energy ≥100 J/cm. These thermal effects can impact tumor response while treating locally advanced mice tumors. Magnetic resonance imaging and thermometry can be used to study these thermal effects. A larger animal model, New Zealand White rabbit with VX2 carcinoma (~5000 mm3) implanted in either the sternomastoid (neck implantation model) or the biceps femoris muscle (thigh implantation model), can be used to study I-PDT with image-based pretreatment planning using computed tomography. In the VX2 model, the light delivery can include the use of multiple laser fibers to test light dosimetry and delivery that are relevant for clinical use of I-PDT.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Interstitial photodynamic therapy; Locally advanced cancer; SCCVII; VX2 carcinoma

Mesh:

Substances:

Year:  2022        PMID: 35505016     DOI: 10.1007/978-1-0716-2099-1_11

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  19 in total

Review 1.  Is there still a role for neoadjuvant chemotherapy in head and neck cancer?

Authors:  L Licitra; J B Vermorken
Journal:  Ann Oncol       Date:  2004-01       Impact factor: 32.976

2.  Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors:  Jarod C Finlay; Timothy C Zhu; Andreea Dimofte; Diana Stripp; S Bruce Malkowicz; Theresa M Busch; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2006 Sep-Oct       Impact factor: 3.421

3.  mTHPC mediated interstitial photodynamic therapy of recurrent nonmetastatic base of tongue cancers: Development of a new method.

Authors:  Baris Karakullukcu; Heike J Nyst; Robert L van Veen; Frank J P Hoebers; Olga Hamming-Vrieze; Max J H Witjes; Sebastiaan A H J de Visscher; Fred R Burlage; Peter C Levendag; Henricus J C M Sterenborg; I Bing Tan
Journal:  Head Neck       Date:  2012-01-31       Impact factor: 3.147

Review 4.  Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions.

Authors:  F R Khuri; D M Shin; B S Glisson; S M Lippman; W K Hong
Journal:  Semin Oncol       Date:  2000-08       Impact factor: 4.929

5.  Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study.

Authors:  Joshua Bauml; Tanguy Y Seiwert; David G Pfister; Francis Worden; Stephen V Liu; Jill Gilbert; Nabil F Saba; Jared Weiss; Lori Wirth; Ammar Sukari; Hyunseok Kang; Michael K Gibson; Erminia Massarelli; Steven Powell; Amy Meister; Xinxin Shu; Jonathan D Cheng; Robert Haddad
Journal:  J Clin Oncol       Date:  2017-03-22       Impact factor: 44.544

Review 6.  ACR appropriateness criteria retreatment of recurrent head and neck cancer after prior definitive radiation expert panel on radiation oncology-head and neck cancer.

Authors:  Mark W McDonald; Joshua Lawson; Madhur Kumar Garg; Harry Quon; John A Ridge; Nabil Saba; Joseph K Salama; Richard V Smith; Anamaria Reyna Yeung; Sue S Yom; Jonathan J Beitler
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-27       Impact factor: 7.038

7.  Platinum-based chemotherapy plus cetuximab in head and neck cancer.

Authors:  Jan B Vermorken; Ricard Mesia; Fernando Rivera; Eva Remenar; Andrzej Kawecki; Sylvie Rottey; Jozsef Erfan; Dmytro Zabolotnyy; Heinz-Roland Kienzer; Didier Cupissol; Frederic Peyrade; Marco Benasso; Ihor Vynnychenko; Dominique De Raucourt; Carsten Bokemeyer; Armin Schueler; Nadia Amellal; Ricardo Hitt
Journal:  N Engl J Med       Date:  2008-09-11       Impact factor: 91.245

8.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Authors:  Robert L Ferris; George Blumenschein; Jerome Fayette; Joel Guigay; A Dimitrios Colevas; Lisa Licitra; Kevin Harrington; Stefan Kasper; Everett E Vokes; Caroline Even; Francis Worden; Nabil F Saba; Lara C Iglesias Docampo; Robert Haddad; Tamara Rordorf; Naomi Kiyota; Makoto Tahara; Manish Monga; Mark Lynch; William J Geese; Justin Kopit; James W Shaw; Maura L Gillison
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

9.  Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer.

Authors:  Sean R H Davidson; Robert A Weersink; Masoom A Haider; Mark R Gertner; Arjen Bogaards; David Giewercer; Avigdor Scherz; Michael D Sherar; Mostafa Elhilali; Joseph L Chin; John Trachtenberg; Brian C Wilson
Journal:  Phys Med Biol       Date:  2009-03-20       Impact factor: 3.609

10.  Interstitial photodynamic therapy as salvage treatment for recurrent head and neck cancer.

Authors:  P-J Lou; H R Jäger; L Jones; T Theodossy; S G Bown; C Hopper
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.